Board / Executive Advisors
During his career in financial services, Neil has worked for Deutsche Bank in various Senior Executive roles & Chief Operating Officer roles. Neil also sits on a number of boards in the technology sector.
As CEO of Etain Health, Amy has extensive experience in the US Cannabis industry. Etain is the leading medical company in New York, from cultivation to production and helping patients in clinics.
Arno is an entrepreneur and until recently a senior partner of McKinsey, where he worked for almost 30 years. He built and led McKinsey´s Global risk management practice and served clients across multiple industries.
Max Wigram has been a successful entrepreneur for more than three decades and has been involved in Eurox since early 2020. He is well experienced in distribution strategies and branding.
Our Co-Chief Executive Officers
As CEO of Dr. Reckeweg & Co. GmbH, David has extensive experience in plant-based medicine and global business development. Since 2019, David has been the President of the European Coalition on Homeopathic & Anthroposophic Medicinal Products.
Bernhard has over 15 years’ experience in regulation & business development globally. Before founding the Eurox Group, he was CEO of Risk Dynamics and Partner in McKinsey.
history of Eurox Pharma
The Eurox Pharma Network
Together with its partners, Eurox Pharma has operations across all continents to produce, manufacture and distribute Cannabis-based Medicines and Products.
Our network of partners combines decades of experience in the pharmaceutical sector, with technical expertise and knowledge across the whole value chain – from production and manufacturing to distribution to other wholesalers and pharmacies, as well as research.
Our overarching aim is to achieve consistently high product quality, stable supply and operational excellence to serve our customers and ultimately the patients who will benefit from our products.
The scientific field of Cannabis-based Medicines and its known benefits for patients are evolving rapidly. Worldwide, there are hundreds of ongoing clinical trials to evaluate the effects of Cannabis-based Medicines. Eurox Pharma is cooperating with leading universities in the field to further contribute to this important scientific progress, and to ensure that our products are up-to-date with the latest research.
Quality / GMP / ProductioN
Eurox Pharma’s comprehensive framework and rigorous approach to regulatory and safety compliance is the cornerstone and quality benchmark for all our activities across the value chain – from cultivation and processing to distribution. To ensure that our operations and products are of highest EU quality and safety standards we are working closely together with national and regional authorities, and scientific and technical experts in GMP and other key areas.
GMP stands for Good Manufacturing Practice. EU-wide GMP regulations and guidelines ensure that all aspects of the development process of a remedy are conducted in accordance with the highest safety and quality standards.
Our core team has a broad knowledge base and extensive experience in European quality requirements and guidelines, as well as national regulatory and safety compliance.
Together with its partners, Eurox Pharma has operations across the whole value chain – from cultivation and manufacturing to distribution to pharmacies and other wholesalers.
We manufacture in a state-of-the-art facility in Germany
One of the largest and most advanced manufacturing facilities for Cannabis-based Medicines and Products in Europe.
- In total 10.000 m² production space, including 7.500 m² GMP-area
- A variety of extraction procedures, such as CO2-extraction, soxhlet and maceration
- Various product forms with significant capacity, including oils, tablets, globules, ointments, injections, nasal spray, and ampoules
A Peek Behind The DoORS